TNF-α inhibitors on par with novel biologics for resolution of dactylitis, enthesitis
Tumour necrosis factor-α (TNF-α) inhibitors infliximab, golimumab and adalimumab are as effective as novel biologic agents ustekinumab, secukinumab and ixekizumab in the treatment of dactylitis and enthesitis, results of a systematic review and meta-analysis have shown.
TNF-α inhibitors on par with novel biologics for resolution of dactylitis, enthesitis
12 Jan 2020